Resumen
Presentamos una revisión respecto a Vigabatrin en el tratamiento de epilepsia en niños, haciendo énfasis en Sindrome de West y epilepsia focal. En el primer caso la evidencia es comparable con la descrita para esteroides, sin embargo la incidencia de efectos colaterales es menor. Es de elección, con adecuado nivel de evidencia, en el manejo de epilepsia causada por esclerosis tuberosa. Se puede recomendar en el manejo de epilepsia focal, vigilando la aparición de crisis paradójicas.
Citas
Lippert B, Mercalf B, Jung M et al. 4-Amino-hex-5-enoic Acid, a Selective Catalytic Inhibitor of 4-Aminobutyric-Acid Aminotransferase in Mammalian Brain. Eur J Biochem 1977; 74: 441-445.
Jung MJ, Lippert B, Metcalf W et al. ?-Vinyl gaba (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-t: effects on brain GABA metabolism in mice. J Neuroch 1977; 29: 797-802.
Krämer G. Vigabatrin. En S. Shorvon, E. Perucca, D. Fish y E. Dodson, editors, The treatment of epilepsy, second edition. Oxford: Blackwell Science, 2004; p. 540-547.
Ben-Menachem E. Vigabatrin. En E. Wyllie, editor, The treatment of epilepsy principles and practice. Philadelphia: Lippincot Williams & Wilkins, 2001; p. 961-968.
Krämer G, Wohlrab G. Vigabatrin. En J. Pellock, B. Bourgeois y E. Dodson, editors, Pediatric epilepsy diagnosis and treatment. New York: Demos, 2008; p. 699-710.
Willmore J, Abelson M, Ben-Menachem E et al. Vigabatrin: 2008 update. Epilepsia 2009; 50: 163-173.
FDA, Center for Drug Evaluation and Research. Hallado en: http:// www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Acceso en diciembre de 2009.
Sills G, Butler E, Thompson G, Brodie M. Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study. Seizure 1999; 8: 404-411.
Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of Vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999; 40: 1627-1633.
Chiron C, Dulac O, Beaumont D et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991; (S2): S52-9.
Aicardi J, Mumford J, Dumas C et al. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Epilepsia 1996; 37: 638-642.
Siemes H, Brandl U, Spohr HL et al. Long term follow up study in vigabatrin pretreated children with West syndrome. Seizure 1998; 7: 293-7.
Granstrom ML, Gaily E, Liukkonen E. Treatment of infantile spasms: results of a population-based study with Vigabatrin as the first drug for spasms. Epilepsia 1999; 40: 950-957.
Elterman RD, Shields WD, Mansfield KA. Randomized trial of Vigabatrin in patients with infantile spasms. Neurology 2001; 57: 1416-1421.
Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997; 38: 1270-1274.
Cossette P, Riviello JJ, Carmant L. ACTH versus Vigabatrin therapy in infantile spasms: a retrospective study. Neurology 1999; 52: 1691-1694.
Lux A, Edwards SW, Hancock B et al. The United Kingdom Infantile Spasms Study comparing Vigabatrin with Prednisolone or Tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004; 364: 1773-1778.
Lux A, Edwards SW, Hancock B et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with Vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005; 4: 712-17.
National Guideline Clearinghouse USA. The diagnosis and management of the epilepsies in adults and children in primary and secondary care; 2008. Hallado en: http://www.guideline.gov.
Mackay MT, Weiss SK, Adams-Weber T, Ashwal S, Stephens D. Practice Parameter: medical treatment of infantile spasm. Neurology 2004; 62: 1668-1681.
Parisi P, Bombardieri R, Curatolo P. Current role of Vigabatrin in infantile spasms. Eur J Paediatr Neurol 2007; 11: 331-336.
Curatolo P, Verdecchia M, Bombardieri R. Vigabatrin for tuberous sclerosis complex. Brain Dev 2001; 23: 649-653.
Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database of Systematic Reviews 2008, Issue 4.
Cohen-Sadan S, Kramer U, Ben-Zeev B. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. Eur J Neurol 2009; 16(4): 482-7.
Camposano S, Major P, Halpern E, Thiele E. Vigabatrin in the treatment of childhood epilepsy: A retrospective chart review of efficacy and safety profile. Epilepsia 2008; 49 (7): 1186-1191.
Fejerman N. Vigabatrin as a first-choice drug in the treatment of West syndrome. J Child Neurol 2000; 15(3): 161-5.
Jambaque I, Chiron C, Dumas C et al. Mental and behavioural outcome of infantile epilepsy treated by Vigabatrin in tuberous sclerosis patients. Epilepsy Res 2000; 38: 151-160.
Nabbout R, Melki I, Gerbaka B et al. Infantile spasms in Down syndrome: Good response to short course of Vigabatrin. Epilepsia 2001; 42: 1580-1583.
Livingston J, Beaumont D, Arzimanoglou A, Aicardi J. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmac 1989; 27: 109S-112S.
Wong V. Open Label Trial with Vigabatrin in children with intractable epilepsy. Brain & Development 1995; 17: 249-252.
Acta Neurol Colomb Vol. 26 No. 1 Suplemento (1:1) Marzo 2010
Coppola G, Maddalena A, Pascotto A. Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. Brain & Development 1997; 19: 459-463.
Gherpelli J et al. Vigabatrin in the refractory childhood epilepsy. The Brazilian multicenter study. Epilepsy research 1997; 29: 1-6.
Prasad A, Penney S, Buckley D. The Role of Vigabatrin in Childhood Seizure Disorders: Results from a Clinical Audit. Epilepsia 2001; 42: 54-61.
Chiron C, Dulac O, Gram L. Vigabatrin withdrawal randomised study in children. Epilepsy research 1996; 25: 209-215.
Gobbi G, Pini A, Bertani G, Menegati E et al. Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies. Epilepsy research 1999; 35: 29-37.
Sobaniec W, Kulak W, Strzelecka J et al. A comparative study of vigabatrin vs carbamazepine in monotherapy of newly diagnosed partial seizures in children. Pharmacological reports 2005; 57: 646-653.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.